Gastrointestinal Medical Oncology Clinic

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Can...

Overall survival is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. The treatment arms will be compared using a stratified C...

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2...

Will be assessed by the proportion of patients who achieve complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) during the protocol treatment. Fisher's exact te...

Recruiting

Comparison of Whole Body DWI to FDG PET

The overall proportion of lesions that will be characterized as positive on whole body (WB) diffusion weight imaging (DWI) and FDG PET.

Recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

ORR is defined as a complete response (CR) or a partial response (PR) according to RECIST version 1.1 criteria. The All Subjects as Treated (ASaT, ITT) population will be used for analysis which consists of all participants who re...

Recruiting

TheraSphere With Durvalumab and Tremelimumab for HCC

Complete response and partial response evaluated by mRECIST.

Recruiting

Addressing the Nutritional Needs of Cancer Survivors With Nutrition Insecurity

The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is c...

Recruiting

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable H...

Tumor-infiltrating immune cells (TIICs) will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab treatment tumor specimens. The proportion of patients with a >= 2-fold increase (from pre- to post-treatment) in...

Recruiting

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients Wit...

Assessment of Dose-limiting toxicities (DLTs)

Recruiting

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

The overall percentage of participants with pathogenic, or likely pathogenic germline mutations will be reported with 95% confidence intervals

Recruiting